ArriVent BioPharma (AVBP) Cash from Operations (2023 - 2026)

ArriVent BioPharma (AVBP) has 4 years of Cash from Operations data on file, last reported at 41892000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 38.4% year-over-year to 41892000.0; the trailing twelve-month figure through Mar 2026 stood at 134472000.0 (down 12.44% YoY), and the FY2025 full-year result was 160588000.0, down 128.72% from the prior year.
• Cash from Operations declined to 41892000.0 in Q1 2026, from 30658000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 8606000.0 in Q2 2023 to a low of 68008000.0 in Q1 2025.
• A 4-year average of 25271846.15 and a median of 18628000.0 in 2024 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations sank 265.08% in 2025 and soared 38.4% in 2026, its largest moves.
• Tracing AVBP's Cash from Operations over 4 years: stood at 14913000.0 in 2023, then slipped by 8.31% to 16152000.0 in 2024, then slumped by 89.81% to 30658000.0 in 2025, then plunged by 36.64% to 41892000.0 in 2026.
• Business Quant data shows AVBP's Cash from Operations at 41892000.0 in Q1 2026, 30658000.0 in Q4 2025, and 35798000.0 in Q3 2025.